The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action

• Philippe A. Gallay ,

  * E-mail: gallay@scripps.edu (PG); rfoster@ciclofilin.com (RF)

  Affiliation Department of Immunology & Microbial Science, The Scripps Research Institute, La Jolla, California, United States of America

  ⨯
• Michael D. Bobardt,

  Affiliation Department of Immunology & Microbial Science, The Scripps Research Institute, La Jolla, California, United States of America

  ⨯
• Udayan Chatterji,

  Affiliation Department of Immunology & Microbial Science, The Scripps Research Institute, La Jolla, California, United States of America

  ⨯
• Daniel J. Trepanier,

  Affiliation Ciclofilin Pharmaceuticals Inc., San Diego, California, United States of America

  ⨯
• Daren Ure,

  Affiliation Ciclofilin Pharmaceuticals Inc., San Diego, California, United States of America

  ⨯
• Cosme Ordonez,

  Affiliation Ciclofilin Pharmaceuticals Inc., San Diego, California, United States of America

  ⨯
• Robert Foster

  * E-mail: gallay@scripps.edu (PG); rfoster@ciclofilin.com (RF)

  Affiliation Ciclofilin Pharmaceuticals Inc., San Diego, California, United States of America

  ⨯